Wing of Bat, Eye of Newt, Slime of Frog ...One of These Actually Cures Flu
Skin secretions from the Indian frog Hydrophylax bahuvistara contain antiviral peptides. One peptide, which Emory researchers named urumin, can physicially destroy H1 influenza virions. Combination photo courtesy of Sanil George and Jessica Shartouny. Emory University/Rajiv Ghandi Center fo Biotechnology
A component of the skin mucus secreted by South Indian frogs can kill the H1 variety of influenza viruses, researchers from Emory Vaccine Center and the Rajiv Gandhi Center for Biotechnology in India have discovered.
Frogs' skins were known to secrete peptides that defend them against bacteria. The finding, published Tuesday in Immunity, suggests that the peptides represent a resource for antiviral drug discovery as well.
Read: anti-flu proteins protect mice
Anti-flu peptides could become handy when vaccines are unavailable, in the case of a new pandemic strain, or when circulating strains become resistant to current drugs, says senior author Joshy Jacob, PhD, associate professor of microbiology and immunology at Emory Vaccine Center and Emory University School of Medicine.
The first author of the paper is graduate student David Holthausen, and the research grew out of collaboration with M.R. Pillai, PhD and Sanil George, PhD from the Rajiv Gandhi Center for Biotechnology.
Jacob and his colleagues named one of the antiviral peptides they identified urumin, after a whip-like sword called "urumi" used in southern India centuries ago. Urumin was found in skin secretions from the Indian frog Hydrophylax bahuvistara, which were collected after mild electrical stimulation.
Peptides are short chains of amino acids, the building blocks of proteins. Some anti-bacterial peptides work by punching holes in cell membranes, and are thus toxic to mammalian cells. Some antiviral peptides from the frogs were toxic in this way, but urumin was not. Instead, it appears to only disrupt the integrity of flu virus, as seen through electron microscopy.
See also: using electron microscopy to image soft materials
"I was almost knocked off my chair," Jacob says. "In the beginning, I thought that when you do drug discovery, you have to go through thousands of drug candidates, even a million, before you get 1 or 2 hits. And here we did 32 peptides, and we had 4 hits."
It turns out that urumin binds the stalk of hemagglutinin, a less variable region of the flu virus that is also the target of proposed universal vaccines. This specificity could be valuable because current anti-influenza drugs target other parts of the virus, Jacob says. Because flu viruses from humans cannot infect frogs, producing urumin probably confers on frogs an advantage in fighting some other pathogen, he says.
Read more: development of universal flu vaccine
Delivered intranasally, urumin protected unvaccinated mice against a lethal dose of some flu viruses. Urumin was specific for H1 strains of flu, such as the 2009 pandemic strain, and was not effective against other current strains such as H3N2.
Developing antimicrobial peptides into effective drugs has been a challenge in the past, partly because enzymes in the body can break them down. Jacob's lab is now exploring ways to stabilize antiviral peptides such as urumin, as well as looking for frog-derived peptides that are active against other viruses like dengue and Zika.
Holthausen, David J. et al. "An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin-Bearing Influenza Viruses" (2017) Immunity , Volume 46 , Issue 4 , 587 - 595
This article has been republished from materials provided by Emory University. Note: material may have been edited for length and content. For further information, please contact the cited source.
Working Together Helps Phage Overcome CRISPRNews
Surprising results show that phage join forces to overcome bacteria’s CRISPR -based immune defenses. Improved understanding of the interactions between phage and their bacterial hosts could help advance phage-based therapies and stimulate viral research.READ MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
Synthetic Material That Detects Enzymatic ActivityNews
Scientists integrate protein and polymer building blocks to create stimulus-responsive systemsREAD MORE